08 November 2021 | News
Meiji Seika Pharma will continue to optimize production bases in Japan and overseas to strengthen production system
image credit- shutterstock
Japan-based Meiji Seika Pharma has announced that it has been decided to construct a new manufacturing facility at Adcock Ingram in Bengaluru, India, to enhance its production capacity of the contract manufacturing organization (CMO) business.
Adcock Ingram, established in 2007, is a joint venture between Adcock Ingram Holdings in South Africa, and India-based Medreich, a wholly-owned subsidiary of Meiji Seika Pharma.
Adcock Ingram manufactures pharmaceutical products, by contract manufacturing, and distributes for the South African, European and Oceanian markets.
By adding the new manufacturing facility, it can manufacture pharmaceutical products not only for the Adcock Ingram Group, but also for other clients. The new manufacturing facility is built at a subsidiary of Adcock Ingram Ltd. and is scheduled to start operation in March 2023.
The Meiji Group's Pharmaceutical Segment, in its "2023 Medium-Term Business Plan", has set an agenda to "Expand CMO/CDMO business" in its business strategies.